Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

[Changes in neuroglial interactions in the cerebral nigrostriatal structures in a model of dopamine system dysfunction].

Voronkov DN, Khudoerkov RM, Dovedova EL.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(7):47-51. Russian.

PMID:
23994921
2.

Effects of short-term exposure to haloperidol and reserpine on dopamine turnover in nigrostriatal system in rat brain.

Dovedova EL, Voronkov DN, Khudoerkov RM.

Bull Exp Biol Med. 2010 Dec;150(2):188-90. English, Russian.

PMID:
21240369
3.

The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system.

Herrera AJ, Castaño A, Venero JL, Cano J, Machado A.

Neurobiol Dis. 2000 Aug;7(4):429-47.

PMID:
10964613
4.

D2 Dopamine receptor blockade results in sprouting of DA axons in the intact animal but prevents sprouting following nigral lesions.

Tripanichkul W, Stanic D, Drago J, Finkelstein DI, Horne MK.

Eur J Neurosci. 2003 Mar;17(5):1033-45.

PMID:
12653979
5.

The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.

Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, Jenner P.

Eur J Neurosci. 2005 Jul;22(2):317-30.

PMID:
16045485
8.

The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.

Datla KP, Bennett RD, Zbarsky V, Ke B, Liang YF, Higa T, Bahorun T, Aruoma OI, Dexter DT.

J Pharm Pharmacol. 2004 May;56(5):649-54.

PMID:
15142343
11.

Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.

Maeda T, Nagata K, Yoshida Y.

Neurosci Lett. 2008 Mar 15;433(3):255-8. doi: 10.1016/j.neulet.2008.01.030. Epub 2008 Jan 18.

PMID:
18255227
12.

Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.

Engler H, Doenlen R, Riether C, Engler A, Niemi MB, Besedovsky HO, del Rey A, Pacheco-López G, Feldon J, Schedlowski M.

Brain Behav Immun. 2009 May;23(4):518-26. doi: 10.1016/j.bbi.2009.01.018. Epub 2009 Feb 7.

PMID:
19486644
13.

Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.

Gouhier C, Chalon S, Aubert-Pouessel A, Venier-Julienne MC, Jollivet C, Benoit JP, Guilloteau D.

Synapse. 2002 Jun 1;44(3):124-31.

PMID:
11954043
15.

Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study.

Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, Imai Y, Araki T.

J Neural Transm (Vienna). 2003 Oct;110(10):1129-44.

PMID:
14523625
17.

Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.

Liu B, Dluzen DE.

Clin Exp Pharmacol Physiol. 2007 Jul;34(7):555-65. Review.

PMID:
17581209
18.

Comparison of the neuroprotective potential of Mucuna pruriens seed extract with estrogen in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice model.

Yadav SK, Prakash J, Chouhan S, Westfall S, Verma M, Singh TD, Singh SP.

Neurochem Int. 2014 Jan;65:1-13. doi: 10.1016/j.neuint.2013.12.001. Epub 2013 Dec 11.

PMID:
24333323
20.

3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra.

Elverfors A, Pileblad E, Lagerkvist S, Bergquist F, Jonason J, Nissbrandt H.

J Neurochem. 1997 Oct;69(4):1684-92.

Supplemental Content

Support Center